GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arcturus Therapeutics Holdings Inc (NAS:ARCT) » Definitions » Tax Rate %

ARCT (Arcturus Therapeutics Holdings) Tax Rate % : 3.05% (As of Sep. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Arcturus Therapeutics Holdings Tax Rate %?

Tax Rate % is calculated as Tax Expense divided by its Pre-Tax Income. Arcturus Therapeutics Holdings's Tax Expense for the three months ended in Sep. 2024 was $-0.2 Mil. Arcturus Therapeutics Holdings's Pre-Tax Income for the three months ended in Sep. 2024 was $-7.1 Mil. Therefore, Arcturus Therapeutics Holdings's Tax Rate % for the quarter that ended in Sep. 2024 was 3.05%.

Arcturus Therapeutics Holdings Tax Rate % Historical Data

The historical data trend for Arcturus Therapeutics Holdings's Tax Rate % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arcturus Therapeutics Holdings Tax Rate % Chart

Arcturus Therapeutics Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Tax Rate %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 12.17 -6.58

Arcturus Therapeutics Holdings Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Tax Rate % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.83 -2.29 -1.39 0.86 3.05

Arcturus Therapeutics Holdings Tax Rate % Calculation

Tax Rate % is the ratio of tax expense divided by pretax income, usually presented in percent.

Arcturus Therapeutics Holdings's Tax Rate % for the fiscal year that ended in Dec. 2023 is calculated as

Tax Rate %=Tax Expense (A: Dec. 2023 )/Pre-Tax Income (A: Dec. 2023 )
=1.835/-27.89
=-6.58 %

Arcturus Therapeutics Holdings's Tax Rate % for the quarter that ended in Sep. 2024 is calculated as

Tax Rate %=Tax Expense (Q: Sep. 2024 )/Pre-Tax Income (Q: Sep. 2024 )
=-0.217/-7.12
=3.05 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arcturus Therapeutics Holdings Tax Rate % Related Terms

Thank you for viewing the detailed overview of Arcturus Therapeutics Holdings's Tax Rate % provided by GuruFocus.com. Please click on the following links to see related term pages.

Arcturus Therapeutics Holdings Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arcturus Therapeutics Holdings Inc (NAS:ARCT) » Definitions » Tax Rate %
Comparable Companies
SVRA ELVN TYRA TBPH TVTX PHAT TRDA ALPN VERA EDIT OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
N/A
Address
10628 Science Center Drive, Suite 250, San Diego, CA, USA, 92121
Website
https://www.arcturusrx.com
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in the research and development segment of medical applications for nucleic acid-focused technology. The company's product pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU and LUNAR-COV19.
Executives
Pad Chivukula officer: Chief Scientific Officer & COO 10628 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO CA 92121
Andy Sassine officer: Chief Financial Officer 82 DEVONSHIRE STREET, BOSTON MA 02109
Keith C Kummerfeld officer: See Remarks 10628 SCIENCE CENTER DRIVE, SUITE 250, SAN DIEGO CA 92121
Magda Marquet director ALTHEADX INC., 3550 DUNHILL STREET, SAN DIEGO CA 92121
John Markels director C/O SANGAMO THERAPEUTICS, INC., POINT RICHMOND TECH CTR, 501 CANAL BLVD., RICHMOND CA 94804
Joseph E Payne director, 10 percent owner, officer: President and CEO 10628 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO CA 92121
Jing L. Marantz director C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Ultragenyx Pharmaceutical Inc. director, 10 percent owner 60 LEVERONI COURT, NOVATO CA 94949
Lance Kurata officer: Chief Legal Officer 10628 SCIENCE CENTER DRIVE, SUITE 250, SAN DIEGO CA 92121
Steven George Hughes officer: Chief Development Officer 6275 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
James F Barlow director 2525 DUPONT DR, IRVINE CA 92612
Edward W Holmes director C/O TULARIK INC, TWO CORP DRIVE SOUTH, SAN FRANCISCO CA 8608257208
Peter C Farrell director RESMED INC, 14040 DANIELSON STREET, POWAY CA 92064-6857
Karah Herdman Parschauer director 60 LEVERONI COURT, NOVATO CA 94949